Dianthus Therapeutics (DNTH) Competitors $20.02 +0.18 (+0.91%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. ARWR, IBRX, OGN, APLS, XENE, NAMS, GMTX, BHC, AGIO, and TWSTShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors Arrowhead Pharmaceuticals ImmunityBio Organon & Co. Apellis Pharmaceuticals Xenon Pharmaceuticals NewAmsterdam Pharma Gemini Therapeutics Bausch Health Cos Agios Pharmaceuticals Twist Bioscience Dianthus Therapeutics (NASDAQ:DNTH) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Do institutionals & insiders hold more shares of DNTH or ARWR? 47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 8.2% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, DNTH or ARWR? Dianthus Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Do analysts prefer DNTH or ARWR? Dianthus Therapeutics currently has a consensus target price of $53.00, suggesting a potential upside of 164.74%. Arrowhead Pharmaceuticals has a consensus target price of $43.71, suggesting a potential upside of 131.91%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Dianthus Therapeutics is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media refer more to DNTH or ARWR? In the previous week, Dianthus Therapeutics had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 4 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.63 beat Dianthus Therapeutics' score of 0.76 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has better earnings & valuation, DNTH or ARWR? Dianthus Therapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$6.24M103.18-$84.97M-$2.88-6.95Arrowhead Pharmaceuticals$3.55M733.29-$599.49M-$1.40-13.46 Is DNTH or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,544.23%. Dianthus Therapeutics' return on equity of -29.26% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-1,544.23% -29.26% -27.87% Arrowhead Pharmaceuticals N/A -45.33%-12.49% SummaryDianthus Therapeutics beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$643.84M$2.93B$5.52B$9.35BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-6.9520.5927.9519.83Price / Sales103.18289.89438.79106.18Price / CashN/A42.3835.5357.53Price / Book1.687.788.255.72Net Income-$84.97M-$55.11M$3.23B$257.51M7 Day Performance-2.86%1.31%-0.13%0.59%1 Month Performance15.92%11.91%7.21%10.74%1 Year Performance-27.67%0.19%27.45%15.87% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.2655 of 5 stars$20.02+0.9%$53.00+164.7%-30.4%$643.84M$6.24M-6.9580ARWRArrowhead Pharmaceuticals3.7504 of 5 stars$18.61+1.6%$43.71+134.9%-38.1%$2.57B$545.21M-13.29400News CoveragePositive NewsIBRXImmunityBio2.1769 of 5 stars$2.90+3.2%$12.25+322.4%-57.0%$2.56B$31.22M-5.00590OGNOrganon & Co.4.8219 of 5 stars$9.83-1.2%$18.00+83.2%-53.7%$2.55B$6.40B3.414,000APLSApellis Pharmaceuticals4.3116 of 5 stars$19.91+2.4%$39.79+99.8%-52.0%$2.50B$781.37M-11.12770Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionXENEXenon Pharmaceuticals3.4549 of 5 stars$32.60+1.2%$54.82+68.2%-26.4%$2.50B$9.43M-10.09210Positive NewsNAMSNewAmsterdam Pharma3.5255 of 5 stars$22.17+2.9%$42.89+93.5%+8.4%$2.49B$47.14M-11.794Analyst ForecastGMTXGemini TherapeuticsN/A$56.91-1.9%N/A+14.3%$2.47BN/A-56.9130BHCBausch Health Cos3.7042 of 5 stars$6.34-1.3%$7.30+15.2%-14.7%$2.34B$9.63B-57.5920,700AGIOAgios Pharmaceuticals4.3958 of 5 stars$39.23+0.5%$58.60+49.4%-16.8%$2.27B$37.04M3.49390Analyst RevisionTWSTTwist Bioscience4.2609 of 5 stars$37.80-0.6%$50.40+33.3%-37.5%$2.26B$312.97M-11.63990 Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Alternatives ImmunityBio Alternatives Organon & Co. Alternatives Apellis Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives Gemini Therapeutics Alternatives Bausch Health Cos Alternatives Agios Pharmaceuticals Alternatives Twist Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts